Rapid Development of Hypertension by Sorafenib: Toxicity or Target?

被引：46
作者：
Humphreys, Benjamin D. [2 ,3 ]
Atkins, Michael B. [1 ,4 ]
机构：
[1] Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA
[3] Dana Farber Canc Inst, Lance Armstrong Fdn Adult Survivorship Program, Boston, MA 02115 USA
[4] Dana Farber Harvard Canc Ctr, Kidney Canc Program, Boston, MA USA
来源：
CLINICAL CANCER RESEARCH | 2009年 / 15卷 / 19期
关键词：
ENDOTHELIAL GROWTH-FACTOR; ANGIOGENESIS; CANCER;
D O I：
10.1158/1078-0432.CCR-09-1717
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Blood pressure elevation is likely a pharmacodynamic marker of VEGF signaling pathway (VSP) inhibition and could be useful for optimizing safe and effective VSP inhibitor dosing. Blood pressure rises on the first day of treatment, facilitating design and interpretation of future trials aiming to correlate blood pressure changes with clinical outcomes. (Clin Cancer Res 2009;15(19):5947-9)
引用
收藏
页码：5947 / 5949
页数：3
相关论文
共 12 条
  • [1] Effect of the Multitargeted Receptor Tyrosine Kinase Inhibitor, ABT-869 [N-(4-(3-Amino-1H-indazol-4-yl)phenyl)-N′-(2-fluoro-5-methylphenyl)urea], on Blood Pressure in Conscious Rats and Mice: Reversal with Antihypertensive Agents and Effect on Tumor Growth Inhibition
    Franklin, Pamela H.
    Banfor, Patricia N.
    Tapang, Paul
    Segreti, Jason A.
    Widomski, Deborah L.
    Larson, Kelly J.
    Noonan, William T.
    Gintant, Gary A.
    Davidsen, Steven K.
    Albert, Daniel H.
    Fryer, Ryan M.
    Cox, Bryan F.
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2009, 329 (03) : 928 - 937
  • [2] Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability
    Fukumura, D
    Gohongi, T
    Kadambi, A
    Izumi, Y
    Ang, J
    Yun, CO
    Buerk, DG
    Huang, PL
    Jain, RK
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (05) : 2604 - 2609
  • [3] Vascular endothelial growth factor vascular permeability factor produces nitric oxide-dependent hypotension - Evidence for a maintenance role in quiescent adult endothelium
    Horowitz, JR
    Rivard, A
    vanderZee, R
    Hariawala, M
    Sheriff, DD
    Esakof, DD
    Chaudhry, GM
    Symes, JF
    Isner, JM
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (11) : 2793 - 2800
  • [4] Kim JJ, 2009, J CLIN ONCOL, V27
  • [5] Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib
    Lacouture, M. E.
    Reilly, L. M.
    Gerami, P.
    Guitart, J.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 (11) : 1955 - 1961
  • [6] Autocrine VEGF signaling is required for vascular homeostasis
    Lee, Sunyoung
    Chen, Tom T.
    Barber, Chad L.
    Jordan, Maria C.
    Murdock, Jared
    Desai, Sharina
    Ferrara, Napoleone
    Nagy, Andras
    Roos, Kenneth P.
    Iruela-Arispe, M. Luisa
    [J]. CELL, 2007, 130 (04) : 691 - 703
  • [7] Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of Treatment
    Maitland, Michael L.
    Kasza, Kristen E.
    Karrison, Theodore
    Moshier, Kristin
    Sit, Laura
    Black, Henry R.
    Undevia, Samir D.
    Stadler, Walter M.
    Elliott, William J.
    Ratain, Mark J.
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (19) : 6250 - 6257
  • [8] A Preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib
    Patel, Tejas V.
    Morgan, Jeffrey A.
    Demetri, George D.
    George, Suzanne
    Maki, Robert G.
    Quigley, Michael
    Humphreys, Benjamin D.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (04): : 282 - U12
  • [9] Rini BI, 2008, J CLIN ONCOL S, V26
  • [10] Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100
    Schneider, Bryan P.
    Wang, Molin
    Radovich, Milan
    Sledge, George W.
    Badve, Sunil
    Thor, Ann
    Flockhart, David A.
    Hancock, Bradley
    Davidson, Nancy
    Gralow, Julie
    Dickler, Maura
    Perez, Edith A.
    Cobleigh, Melody
    Shenkier, Tamara
    Edgerton, Susan
    Miller, Kathy D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (28) : 4672 - 4678
12